Clever Culture Systems Ltd
16 Anster St
Adelaide SA 5000
www.cleverculturesystems.com

ASX:CC5

CHAIR'S ADDRESS TO THE 2025 ANNUAL GENERAL MEETING

Rebecca Wilson, Chairperson

Adelaide, Australia, 17 November 2025

Good morning everyone, and welcome. It's wonderful to see familiar faces who have supported our company for many years, and pleasingly many new ones who see the opportunity for our future. Thank you for making the time to be here and for being such an important part of our Clever Culture Systems' story.

FY25 has been a defining year for our Company, a year that reflects our progress, our resilience, and our promise. For the last few years, we've been rebuilding, evolving and adapting our technology, creating new opportunities, and proving our value proposition in the highly regulated world of pharmaceutical microbiology. This year, those foundations began to pay off commercially. We delivered profitability, positive cash flows, and strengthened the balance sheet, all while expanding our presence with some of the world's largest pharmaceutical companies.

Our APAS® Independence technology continues to lead the field as the world's only FDA-cleared AI system for automated culture plate reading. It delivers certainty, speed, and data integrity, three things that are critical in the manufacturing of pharmaceutical products. Importantly, this unique capability is resonating across the global pharmaceutical manufacturing community.

We don't take this distinction lightly. It represents years of rigorous development and testing, and positions us uniquely, especially as regulators continue to tighten requirements to ensure safe and effective drugs are supplied to patients globally.

Over the past year, we have made major commercial gains. We've secured multi-instrument orders from AstraZeneca and Bristol Myers Squibb, with Pfizer undertaking an active evaluation program. Pleasingly this last quarter we've secured new contracts with Novo Nordisk and Boehringer Ingleheim, adding to our growing global customer base and two important leaders in sterile drug manufacturing, bringing our total number of major pharmaceutical companies now using APAS® Independence to six.

Our sales pipeline now exceeds 150 APAS® Independence instruments[1], representing over $75 million in potential upfront sales revenue and up to $15 million in annual recurring revenues[2]. And crucially, the environment we're operating in is expanding rapidly. We estimate the total addressable market for APAS® Independence is valued at around US $2.8 billion, with overarching tailwinds driven by stricter regulatory oversight, the rise of complex biologics manufacturing, and industry-wide movement toward automation that reduces manual workflows and improves digital traceability.

These are powerful structural forces; forces that play directly to our strengths.

In FY25, we advanced our next innovation step: the launch of an APAS® analysis module for 55mm contact plates. This represents an important expansion of the APAS® platform, allowing automation of both settle and contact plates on one system, increasing the efficiency and economics for our customers while deepening recurring revenue potential for the business.

Financially, we've strengthened the company's position considerably. In addition to growing revenues, I'm pleased to share that over 99% of outstanding options were exercised by the close off date of 15th November, contributing a further $1.1 million since the end of September, which is after repaying in full our loan from the South Australian government. I'd like to take the opportunity to thank the South Australian Financing Authority team for their partnership and flexibility in supporting us over prior years. This strong uptake reflects clear shareholder confidence. These resources have allowed us to reduce debt, enhance our cash position, and improve flexibility for future investment.

But I also want to take a moment to reflect, not just on progress, but on the journey that brought us here.

We recognise that many shareholders have stood by us during prior challenging years. Two years ago, the Company executed a complete strategy reset, aligned with the pivot to enter the pharmaceutical microbiology market. This was a difficult

---

[1] CCS management estimate based on customer discussions
[2] Sales estimate range is based on the potential number of APAS® instruments sold to current APAS users at an indicative average revenue per instrument sale of $0.5 million (AUD) and recurring annual service and software fees of 20% of the instrument sales price. Assumes a USD:AUD exchange rate of 0.65. The amount is not risk weighted.

time for all Shareholders, who were faced with a decision to reinvest in the revised strategy or walk-away. Your loyalty, patience, and belief have been essential. The board is heavily invested alongside all Shareholders, and the shared commitment has made this turnaround possible.

We know that we are only just at the starting line. FY25 has been our foundational year, where we've proved the product proposition and established traction. From here, the opportunity is significant, but it is how we execute that will define our success. And that focus on disciplined, high-quality execution underpins everything we are planning as we enter the next phase of growth.

Following today's meeting, we'll hold a shareholder event, an opportunity to take you deeper into our business, our technology, our market, and the opportunities in front of us. We want our future to be transparent, where our shareholders can gain a clearer understanding of how we're positioning ourselves to capitalise on global growth in pharmaceutical automation.

And tomorrow, the board will reconvene for our next strategy day. Our conversation will centre on both execution excellence and planning for scale.

I also want to take this opportunity to express my personal thanks to our CEO, Brent Barnes, for his leadership during this important period of transition, and to the entire management team and staff for their commitment and energy. And, finally, I extend my appreciation to my fellow directors for their guidance, insight, and unwavering support through the past year. Their contributions continue to shape a culture of discipline and ambition across the company.

Back to you, our shareholders, truly thank you. We value your continued trust in this company and our direction.

We are building Clever Culture Systems to be the global standard in environmental monitoring automation. That ambition requires us to move with both urgency and discipline. I believe we've struck that balance well this year, and I'm confident in our ability to maintain it as we scale.

Thank you for being here today, and for being part of the Clever Culture journey.

Approved for release by the CCS Board.

– ENDS –

About Clever Culture Systems
Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com